MoBiT

MoBiT:

 Leading product BAB-05 is in late preclinical stage of development. Outstanding efficacy and safety profiles have been demonstrated in rodents and NHP. IND application is expected in Q4/2026 

BAB-05 is a novel monovalent TAA-Directed CD3 T Cell Engager for Hematological Malignancies:
  • High and selective binding affinity to CD19, and optimized T cell engagement with calibrated, moderate affinity for CD3
  • High production yield in stable CHO expression system(4.6g/L in 15L bioreactor)
  • High homogeneity and stability, similar to those of mAbs,
  • Formulation and biophysical properties suitable for subcutaneous administration
  • Induces only modest cytokine release while maintaining enhanced T-cell–dependent cytotoxicity against CD19⁺target cells
  • Induces rapid and sustained depletion of B cells, and enhances T-cell expansion and functional activation
  • Long-actingin NHP (T1/2:4-5 days) with low cytokine release and no observable toxicity at a 4 mg/kg dose
  • Broad indications of B-cell hematological tumorsand B-cell autoimmune diseases
Scroll to Top